Torrent Pharma, the flagship company of Torrent Group, is ranked amongst the top pharma companies of India. It is a dominant player in the therapeutic areas of cardiovascular (CV) and central nervous system (CNS) and has achieved significant presence in gastro-intestinal, diabetology, anti-infective and pain management segments. It has also forayed into the therapeutic segments of nephrology and oncology while also strengthening its focus on gynecology and pediatric segments. Right from pioneering niche marketing in India to earning the sobriquet of ‘the Company with the most first launches’, Torrent Pharma has always remained ahead of its competition. Torrent Pharma’s competitive advantage stems from its world-class manufacturing facilities, advanced R&D capabilities, extensive domestic network and a widespread global presence. It has three world-class manufacturing facilities at Indrad (Gujarat), Baddi (Himachal Pradesh) and Sikkim. The facilities are approved by USFDA, WHO, MHRA, TGA and other global regulatory bodies.

Torrent Pharma has crossed many geographical boundaries with presence in more than 40 countries. The Company is ranked first amongst Indian Companies for having largest market share in Brazil and Germany. Therapeutic Areas Torrent Pharma, the flagship company of the Torrent Group, is one of the leading Pharma companies in India. Jan 27, 2018 - 16 ANDAs filed in FY17, including 2 derma products and FTFs. 25 ANDAs pending including 3 TAs. Torrent Pharmaceuticals 3 Edelweiss.

A new facility is taking shape at Dahej SEZ in Western India, which will cater to the international markets. Torrent Pharma is the sole manufacturer of Insulin Formulations for Novo Nordisk in India since the early ‘90s and has also set up a dedicated formulation and packaging facility for Insulin. Source: Torrent Pharmaceuticals Ltd: Leader in the pharmaceutical industry 2015 Torrent Pharma recognized as the Most Promising Company of the Year at the 10th CNBC TV18 India Business Leader Awards 2014. 2014 Acquired Elder Pharma’s Indentified Indian Branded Formulation Business in India and Nepal. 2011 Forayed into oncology segment. 2006 The API and formulations manufacturing facilities located at Indrad (Gujarat, India) got USFDA approval.

2000 Torrent Pharma bagged the Gold Trophy for IDMA Quality Excellence Award for its Formulations facility. Updated: January, 2015. • • • • • • • • • • • • • • • • • • • • • • Copyright © 2010-2019 India Brand Equity Foundation All material, information, data, images or content on this website is subject to copyright or other applicable intellectual property laws and no part of it can be reproduced in any form (including paper or electronic form) without prior written consent and approval from IBEF.

Infringements are subject to prosecution under the applicable laws. For consent related queries and conditions, please write to An initiative of the.

Ahmedabad based Torrent Pharma enters New Year 2016 by announcing the launch of biosimilar Adalimumab in India under the brand name ‘Adfrar’. Adalimumab is the most preferred therapy for the treatment of auto immune disorders and has wide applications like Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Ulcerative Colitis and Plaque Psoriasis. Adalimumab is the largest selling drug across the globe (innovator brand Humira has sales of 15 billion USD).

Tech Tip: The will back up your current drivers for you. If you encounter any problems while updating your drivers, you can use this feature to restore your previous drivers and configuration settings. Acer crystalbrite lcd driver download windows 10.

Torrent’s brand ‘Adfrar’ will be the second biosimilar Adalimumab in the world. Autoimmune disorders are growing ailments and Monoclonal Antibodies (MAb’s) are becoming mainstay of treatment, therefore launch of ‘Adfrar’ is a significant step towards fortifying its presence in MAb market. Biosimilar Rituximab - ‘Toritz RA’ is already launched in Rheumatology segment and now with launch of biosimilar Adalimumab - ‘Adfrar’, Torrent presence in this segment will get a major fillip, making it a significant player in this super speciality. ‘Adfrar’ will be available as Pre Filled Syringe of 40mg. Torrent will promote this biosimilar to Rheumatologists, Gastroenterologists and Dermatologists pan India, for which three separate super specialty task force have been introduced.

Around 100 highly trained professionals are employed in these Greenfield divisions. This super speciality team, besides promoting biosimilar Adalimumab – ‘Adfrar IB’ to Gastroenterologists, will also cater to the advanced therapy needs in Hepatology. Torrent has launched new generation Hep C Antiviral Sofosbuvir – ‘Sofocruz’, a combination of Sofosbuvir + Ledipasvir - ‘Sofocruz LP’ and Daclatasvir – ‘Daclacruz’. Moreover, the company has also launched Hep B Antiviral Tenofovir – ‘Tenocruz’. Torrent is already marketing biosimilar Rituximab ‘Toritz’ in Oncology segment, while a super specialty division for Nephrology launched in 2014 is marketing biosimilar Darbepoetin alpha - ‘Darbatitor’. Regarding the expected business from these biosimilars, Executive Director - Marketing of Torrent Pharma Mr.Ruchir Modi said that since inception, its focus was never with business intent alone, rather it is a by product.